- Home
- SST vs BLRX Comparison
SST vs BLRX Comparison
Compare SST & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | BLRX |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 11.7M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SST | BLRX |
|---|---|---|
| Price | $2.34 | $2.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 562.9K | 12.7K |
| Earning Date | 11-04-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $266,129,000.00 | N/A |
| Revenue This Year | N/A | $37.33 |
| Revenue Next Year | $21.02 | $37.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $2.15 |
| 52 Week High | $8.19 | $4.50 |
Technical Indicators
Market Signals| Indicator | SST | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 32.06 |
| Support Level | $2.23 | $2.18 |
| Resistance Level | $2.78 | $2.56 |
| Average True Range (ATR) | 0.36 | 0.13 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 3.83 | 4.26 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.